A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma
Public ClinicalTrials.gov record NCT00866333. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will evaluate the efficacy and safety of entinostat, SNDX-275, in patients with relapsed or refractory Hodgkin's lymphoma.
Study identification
- NCT ID
- NCT00866333
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 49 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 12, 2009
- Primary completion
- Feb 7, 2013
- Completion
- Feb 7, 2013
- Last update posted
- Oct 21, 2019
2009 – 2013
United States locations
- U.S. sites
- 6
- U.S. states
- 6
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Tower Cancer Research Foundation | Beverly Hills | California | — | — |
| University of Colorado | Denver | Colorado | — | — |
| Johns Hopkins | Baltimore | Maryland | — | — |
| University of Nebraska Medical Center | Omaha | Nebraska | — | — |
| Roswell Park Cancer Institute | Buffalo | New York | — | — |
| MD Anderson Cancer Center | Houston | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Hodgkin's Lymphoma trials
Other public records listing Hodgkin's Lymphoma. Sorted by last update posted; newest first. Not a recommendation.
- NCT05355051: A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma Recruiting
- NCT01788839: Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma Recruiting
- NCT01192464: EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma Active, not recruiting
- NCT01483664: Communication Skills Intervention to Promote Transition Into Survivorship Active, not recruiting
- NCT02917083: CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00866333, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 21, 2019 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00866333 live on ClinicalTrials.gov.